secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0001104659-24-081680
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar's iopofosine I 131 hits primary endpoint in WM pivotal study; 56.4% MRR
--------------------------------------------------------------------------------

- CLOVER WaM study met primary endpoint: MRR 56.4% (95% CI 42-67%) vs 20% agreed target.
- ORR of 80% and disease control rate 98.2% in heavily pre-treated WM patients (median 4 prior therapies).
- 78% of major responders progression-free at 18 months; median DoR not reached.
- Company plans to submit NDA in Q4 2024 and seek priority review.
- Preliminary cash and equivalents ~$25.9M as of June 30, 2024 (unaudited, subject to change).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924081680/0001104659-24-081680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924081680/tm2419979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-081680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer